Ozenoxacin: A Novel Topical Quinolone for Impetigo

Wren, Christopher; Bell, Edward; Eiland, Lea S.

doi:10.1177/1060028018786510

Cited by 16 publications

(17 citation statements)

References 20 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ozenoxacin is a non-fluorinated quinolone with dual activity against bacterial gyrase and topoisomerase IV and currently used in the treatment of impetigo 76. It has excellent bactericidal activity against Methicillin-sensitive S. aureus, MRSA, MRSE, S. pyogenes, P. acnes and ofloxacin-resistant strains of S. aureus and S. epidermidis 77.…”

Section: Fluoroquinolonesmentioning

confidence: 99%

Potential new fluoroquinolone treatments for suspected bacterial keratitis

et al. 2022

View full text Add to dashboard Cite

Topical fluoroquinolones (FQs) are an established treatment for suspected microbial keratitis. An increased FQ resistance in some classes of bacterial pathogens is a concern. Some recently developed FQs have an extended spectrum of activity, making them a suitable alternative for topical ophthalmic use. For example, the new generation FQs, avarofloxacin, delafloxacin, finafloxacin, lascufloxacin, nadifloxacin, levonadifloxacin, nemonoxacin and zabofloxacin have good activity against the common ophthalmic pathogens such asStaphylococcus aureus,Pseudomonas aeruginosa,Streptococcus pneumoniaeand several of theEnterobacteriaceae. However, because there are no published ophthalmic break-point concentrations, the susceptibility of an isolated micro-organism to a topical FQ is extrapolated from systemic break-point data and wild type susceptibility. The purpose of this review is to compare the pharmacokinetics and pharmacodynamics of the FQs licensed for topical ophthalmic use with the same parameters for new generation FQs. We performed a literature review of the FQs approved for topical treatment and the new generation FQs licensed to treat systemic infections. We then compared the minimum inhibitory concentrations (MIC) of bacterial isolates and the published concentrations that FQs achieved in the cornea and aqueous. We also considered the potential suitability of new generation FQs for topical use based on their medicinal properties. Notably, we found significant variation in the reported corneal and aqueous FQ concentrations so that reliance on the reported mean concentration may not be appropriate, and the first quartile concentration may be more clinically relevant. The provision of the MIC for the microorganism together with the achieved lower (first) quartile concentration of a FQ in the cornea could inform management decisions such as whether to continue with the prescribed antimicrobial, increase the frequency of application, use a combination of antimicrobials or change treatment.

show abstract

Section: Fluoroquinolonesmentioning

confidence: 99%

Potential new fluoroquinolone treatments for suspected bacterial keratitis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Ozenoxacin has bactericidal action against gram-positive organisms including MSSA (methicillin-sensitive Staphylococcus aureus), MRSA (methicillin-resistant Staphylococcus aureus), MRSE (methicillin-resistant Staphylococcus epidermidis), Streptococcus pyogenes, Propionibacterium acnes and ofloxacin-resistant strains of S. aureus and S. epidermidis. [19][20][21] The antibacterial activity of ozenoxacin has been found to be highly superior and the MIC lower, compared to other quinolones such as ofloxacin, nadifloxacin, and levofloxacin. 20 Ozenoxacin also been demonstrated to produce more rapid microbiological clearance compared to retapamulin, although the overall clinical efficacy at the end of treatment has been reported to be similar.…”

Section: Antimicrobial Spectrummentioning

confidence: 99%

Ozenoxacin: A novel topical antibiotic

Santhosh¹,

Thomas

2021

IJDVL

View full text Add to dashboard Cite

show abstract

“…Ozenoxacin (trade name Ozaenex/Xepi), developed by Ferrer International S.A., is a novel, non-fluorinated, topical quinolone that is bactericidal against many Gram-positive organisms, including MRSA, MSSA, MRSE and S. pyogenes [137]. In vitro, MIC 90 values against bacteria such as MSSA, MRSA, S. epidermis was between two- and >16,000-fold greater than compared to other commonly prescribed antibiotics, such as ofloxacin, levofloxacin, erythromycin and gentamicin [138].…”

Section: Novel Anti-gram-positive Antibioticsmentioning

confidence: 99%

“…In vitro, MIC 90 values against bacteria such as MSSA, MRSA, S. epidermis was between two- and >16,000-fold greater than compared to other commonly prescribed antibiotics, such as ofloxacin, levofloxacin, erythromycin and gentamicin [138]. Previous trials demonstrated a complete lack of systemic absorption and no formation of metabolites when ozenoxacin was applied topically, likely contributing to the absence of drug interactions [137]. As a result, the elimination of ozenoxacin has not been investigated in humans [139].…”

Section: Novel Anti-gram-positive Antibioticsmentioning

confidence: 99%

“…The FDA approved ozenoxacin in November 2017 for the treatment of impetigo caused by S. aureus and S. pyogenes in both adults and pediatric patients older than two months of age [21,137]. This was based on two multi-center, randomized, phase III clinical trials evaluating the safety and efficacy of ozenoxacin cream in patients with non-bullous or bullous impetigo (NCT01397461 and NCT02090764) [137]. Ozenoxacin demonstrated superior clinical success compared to the placebo after five days of therapy and superior microbiological success after two days of therapy [141].…”

Section: Novel Anti-gram-positive Antibioticsmentioning

confidence: 99%

See 1 more Smart Citation

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Koulenti

Mok

et al. 2019

Microorganisms

View full text Add to dashboard Cite

Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel antibiotics effective against Gram-positive bacteria has been approved. This review will discuss the current evidence for novel branded antibiotics that are highly effective in the treatment of multidrug-resistant infections by Gram-positive pathogens, namely ceftobiprole, ceftaroline, telavancin, oritavancin, dalbavancin, tedizolid, besifloxacin, delafloxacin, ozenoxacin, and omadacycline. The mechanism of action, pharmacokinetics, microbiological spectrum, efficacy and safety profile will be concisely presented. As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future.

show abstract

Ozenoxacin: A Novel Topical Quinolone for Impetigo

Abstract: Ozenoxacin, the first nonfluorinated quinolone, is a safe, topical treatment for impetigo in patients 2 months of age and older. Although clinical trials demonstrate efficacy compared with placebo, comparative trials to current treatment options are needed to identify its therapeutic use.

Cited by 16 publications

References 20 publications

Potential new fluoroquinolone treatments for suspected bacterial keratitis

Potential new fluoroquinolone treatments for suspected bacterial keratitis

Ozenoxacin: A novel topical antibiotic

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Contact Info

Product

Resources

About